Subscribe
stockstudio-shutterstock-com
StockStudio / Shutterstock.com
18 May 2016Americas

Pfizer buys Anacor for $5.2bn

Pfizer has announced that it will be buying Anacor Pharmaceuticals for $5.2 billion, which will lead to it adding an experimental treatment for eczema, called Crisaborole, to its portfolio.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Flatwing fails to shift attorney fees to Pfizer unit, Anacor
29 June 2021   Generic drug maker Flatwing Pharmaceuticals has lost its bid to offset nearly $690,000 in fees and expenses to Pfizer unit Anacor Pharmaceuticals after a US federal judge ruled that the “circumstances were not exceptional” enough to warrant the shift.
Americas
Actavis and Pfizer settle Celebrex litigation
29 April 2014   Actavis has entered into an agreement with Pfizer to settle all outstanding patent litigation related to Pfizer’s arthritis drug Celebrex (celecoxib).


Editor's picks

UKIPO rejects Boehringer’s SPC for horse inhaler
Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025

Editor's picks

Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025
Americas
Bankruptcy judge approves $305m sale of genetics testing company
1 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

More on this story

Americas
Flatwing fails to shift attorney fees to Pfizer unit, Anacor
29 June 2021   Generic drug maker Flatwing Pharmaceuticals has lost its bid to offset nearly $690,000 in fees and expenses to Pfizer unit Anacor Pharmaceuticals after a US federal judge ruled that the “circumstances were not exceptional” enough to warrant the shift.
Americas
Actavis and Pfizer settle Celebrex litigation
29 April 2014   Actavis has entered into an agreement with Pfizer to settle all outstanding patent litigation related to Pfizer’s arthritis drug Celebrex (celecoxib).

More on this story

Americas
Flatwing fails to shift attorney fees to Pfizer unit, Anacor
29 June 2021   Generic drug maker Flatwing Pharmaceuticals has lost its bid to offset nearly $690,000 in fees and expenses to Pfizer unit Anacor Pharmaceuticals after a US federal judge ruled that the “circumstances were not exceptional” enough to warrant the shift.
Americas
Actavis and Pfizer settle Celebrex litigation
29 April 2014   Actavis has entered into an agreement with Pfizer to settle all outstanding patent litigation related to Pfizer’s arthritis drug Celebrex (celecoxib).

More features

Chicago firm Much Shelist adds partner with ‘entrepreneurial mindset’
Powell Gilbert launches Düsseldorf office with leading patent litigator
Startups toolkit: Why investors want more than patents
J&J fends off generic schizophrenia drug bids
Kilpatrick adds ‘seasoned litigator’ as trademark partner
WATCH: An update on EPO Board of Appeal strategy for 2025 and beyond
Startup challenges rival over brain monitoring tech at ITC
UKIPO rejects Boehringer’s SPC for horse inhaler